Stone Warren 4

What Happened

• Warren Stone, President & Chief Operating Officer of Neogenomics (NEO), reported an open-market sale of 22,128 shares on 2026-01-20 at $12.50 per share, for total proceeds of $276,682. This was a sale (S) transaction — commonly a routine disposition rather than a purchase signal.

Key Details

• Transaction date and price: 2026-01-20, 22,128 shares sold at $12.50 each.
• Proceeds: $276,682.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing/timeliness: Form filed 2026-01-21 for a 2026-01-20 transaction — appears timely based on standard Form 4 rules.
• Notable footnotes: filing shows Mr. Stone holds multiple equity awards (stock options, restricted stock units, performance stock units) from grants in 2022–2025, including grants on Feb 21, 2025 and Apr 1, 2025 with modified vesting following his promotion. Some options are premium-price options (exercise price based on 110% of a prior close). Performance awards have revenue and share-price based vesting metrics.

Context

• This transaction is a straight sale (no exercise/covering details in the excerpt). Sales by executives can be for many reasons (diversification, tax planning, liquidity) and are not, by themselves, proof of negative company outlook. Mr. Stone is an executive (not indicated as a 10% owner in the excerpt) and also holds substantial unvested awards subject to future vesting and performance conditions.